Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World February 23, 2015 Phillip Broadwith	Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
The Motley Fool February 24, 2011 Brian D. Pacampara	Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan.
The Motley Fool March 30, 2011 Brian Orelli	Valeant Vultures Will Cephalon manage to rebuff Valeant's advances?
Chemistry World October 10, 2014 Phillip Broadwith	Endo outbids QLT for Auxilium merger US biotech Auxilium has backed out of a merger with Canadian firm QLT, in favor of a deal with US-based Endo.
Chemistry World July 30, 2013 Emma Stoye	Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb.
The Motley Fool August 19, 2011 Cindy Johnson	12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them?
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool May 10, 2011 Frank Vinluan	Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market?
The Motley Fool December 17, 2011 Matt Koppenheffer	This Week's Top Stock Gainers It wasn't a great week for the market, but some stocks and sectors were able to come out of it ahead of the rest.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
The Motley Fool June 24, 2005 Brian Gorman	Salix's Strange Deal Salix announced that it will buy Inkine in an all-stock acquisition valued at $190 million. At first glance, the two companies appear to be a good strategic fit, since both specialize in marketing gastrointestinal drugs. However, the agreement seems to have more weaknesses than strengths.
The Motley Fool December 20, 2011 Brian D. Pacampara	Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor.
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
The Motley Fool November 6, 2007 Brian Lawler	The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good.
The Motley Fool April 30, 2008 Brian Lawler	The Start of a New Endo The drugmaker marks its first quarter under new management.
The Motley Fool April 12, 2011 Arundhati Parmar	Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company.
The Motley Fool April 30, 2007 Brian Lawler	Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note.
The Motley Fool February 26, 2007 Brian Lawler	Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways.
The Motley Fool August 1, 2007 Brian Lawler	Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments.
The Motley Fool January 19, 2007 Brian Lawler	The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price.
The Motley Fool January 30, 2008 Brian Lawler	The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns.
The Motley Fool February 25, 2008 Brian Lawler	The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness.
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.
The Motley Fool January 10, 2007 Brian Lawler	Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals.
The Motley Fool January 22, 2007 Brian Lawler	The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned.
Chemistry World September 2, 2013 Emma Stoye	Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business.
The Motley Fool April 12, 2011 Sean Williams	This Deal May Be Doomed From the Start See why Level 3's purchase of Global Crossing might be set up to fail.
The Motley Fool October 23, 2006 Brian Lawler	Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool March 12, 2009 Robert Steyer	A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another.
The Motley Fool September 22, 2010 Seth Jayson	Will Endo Pharmaceuticals Holdings Whiff on Revenues Next Quarter? Is Endo Pharmaceuticals sending any warning signs? Take a look at its accounts receivable and days sales outstanding for a clue.
The Motley Fool August 3, 2007 Brian Lawler	Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown.
Chemistry World October 8, 2014 Rebecca Trager	US tax changes ripple into merger deals The tightened tax rules are pressuring pharmaceutical and medical devices companies to reconsider deals announced recently, according to financial analysts.
The Motley Fool February 25, 2011 Brian Orelli	When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections?
The Motley Fool April 1, 2008 Brian Lawler	The Endo a Patent? Endo sues to protect a lead drug from generic competition.
The Motley Fool April 30, 2007 Brian Orelli	No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note.
The Motley Fool August 24, 2010 Travers & Jayson	Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years
Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
The Motley Fool June 14, 2011 Frank Vinluan	GSK Epilepsy Drug Approved by FDA GlaxoSmithKline and drug partner Valeant Pharmaceuticals have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance.
The Motley Fool December 30, 2010 Brian Orelli	That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday.
BusinessWeek November 21, 2005 Gene G. Marcial	Salix Pharmaceuticals: What The Gut Tells You The small fry in gastrointestinal drugs is a pure play in that growing market.
The Motley Fool January 11, 2011 Seth Jayson	Here's How Endo Pharmaceuticals Is Making You So Much Cash With questionable cash flows actually reducing operating cash flow slightly, Endo Pharmaceuticals' cash flows look clean.
The Motley Fool December 28, 2007 Brian Lawler	Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug.
The Motley Fool August 18, 2010 Travers & Jayson	Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders.
The Motley Fool October 3, 2007 Brian Lawler	FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova.
BusinessWeek June 16, 2011 Mider & McCracken	M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying.
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions